Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous SVF for Vocal Fold Scar
NCT05354544Phase 1Terminated
- Start
- Aug 2021
- Primary completion
- Dec 2024
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous adipose-derived stromal vascular fraction in vocal fold scar. Primary endpoint: Adverse events post SVF administration at 24 months. Started Aug 2021; status: terminated.
02
Drugs
autologous adipose-derived stromal vascular fraction
03
Conditions
vocal fold scar
Beyond the preview
Go deeper on NCT05354544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05354544.